Proteomics International Advances Precision Diagnostics with New Launches and Strategic Developments

Proteomics International Laboratories Ltd. ( (AU:PIQ) ) has provided an update.

Proteomics International Laboratories Ltd announced significant advancements in its operations, including the launch of the PromarkerD predictive test for diabetic kidney disease in Australia, which outperforms conventional tests. The company also opened a CLIA certified reference laboratory in California and secured a new Australian patent for its OxiDx technology. These developments are part of Proteomics International’s strategy to commercialize its suite of precision diagnostic tests, leveraging the growing telehealth market and direct-to-consumer healthcare trends to enhance its industry positioning and offer scalable, cost-effective diagnostic solutions.

More about Proteomics International Laboratories Ltd.

Proteomics International Laboratories Ltd is a pioneer in precision diagnostics, focusing on the development and commercialization of novel diagnostic tests using its proprietary Promarker® biomarker discovery platform. The company operates in the precision medicine industry, offering predictive diagnostics and specialist analytical services, with a market focus on addressing unmet medical and commercial needs.

YTD Price Performance: -51.25%

Average Trading Volume: 133,814

Technical Sentiment Signal: Buy

Current Market Cap: A$51.09M

See more insights into PIQ stock on TipRanks’ Stock Analysis page.